Status: Recruiting
Tirzepatide in PWS, HO and GNSO
This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.
Participants needed: 36
Trial details
Phase: Phase 4Age: 18-26Biological sex: AllType: InterventionalSponsor: Grace KimUpdated: Sep 16, 2025Locations: 3
Eligibility criteria
Individuals 18-26 years with a BMI in the obesity range (BMI ≥95th percentile fo... [+6]
Current or recent (within 3 months of start of study drug initiation) use of wei... [+19]